Treatment age and neurocognitive outcomes following proton beam radiotherapy for pediatric low- and intermediate-grade gliomas.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
08 2021
Historique:
revised: 12 04 2021
received: 11 03 2021
accepted: 16 04 2021
pubmed: 22 5 2021
medline: 12 3 2022
entrez: 21 5 2021
Statut: ppublish

Résumé

The relationship between age and neurocognitive functioning following proton beam radiotherapy (PRT) in low- and intermediate-grade gliomas (LIGG) has yet to be examined. Eighteen LIGG patients treated with PRT were prospectively enrolled and received annual neurocognitive evaluations of perceptual/verbal reasoning, working memory, and processing speed postradiotherapy. The median age at diagnosis was 8.2 years (range 1.0-14.7) and the median age at PRT was 9.9 years (range 4.2-17.0). Patients' neurocognitive performance did not change on any measure following PRT (p ≥ .142). We did not observe significant changes in cognitive function over time among a small group of LIGG patients treated with PRT.

Identifiants

pubmed: 34019329
doi: 10.1002/pbc.29096
pmc: PMC9040342
mid: NIHMS1794860
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e29096

Subventions

Organisme : NCI NIH HHS
ID : K07 CA157923
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA187202
Pays : United States

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Lancet Neurol. 2009 Sep;8(9):810-8
pubmed: 19665931
Psychooncology. 2008 Nov;17(11):1157-61
pubmed: 18636431
Pediatr Blood Cancer. 2019 Sep;66(9):e27800
pubmed: 31134755
J Clin Oncol. 2001 Aug 1;19(15):3470-6
pubmed: 11481352
J Clin Oncol. 2009 Aug 1;27(22):3691-7
pubmed: 19581535
Cancer. 2003 May 15;97(10):2512-9
pubmed: 12733151
Neuro Oncol. 2011 Feb;13(2):223-34
pubmed: 21177781
J Neurooncol. 2019 Jan;141(2):413-420
pubmed: 30467811
Psychooncology. 2013 Aug;22(8):1731-7
pubmed: 23059621
Lancet Oncol. 2016 Mar;17(3):287-298
pubmed: 26830377
Neuro Oncol. 2021 Jul 1;23(7):1173-1182
pubmed: 33543269
Strahlenther Onkol. 2016 Nov;192(11):759-769
pubmed: 27363701
J Clin Oncol. 2009 Aug 1;27(22):3598-604
pubmed: 19581536
Pediatr Blood Cancer. 2004 May;42(5):461-4
pubmed: 15049021

Auteurs

Andrew M Heitzer (AM)

Psychology Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Lisa S Kahalley (LS)

Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas, USA.

Charles G Minard (CG)

Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, USA.

Claire Stafford (C)

Psychology Department, Macalester College, St. Paul, Minnesota, USA.

David R Grosshans (DR)

Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

M Fatih Okcu (MF)

Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.

Kimberly P Raghubar (KP)

Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas, USA.

Marsha Gragert (M)

Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas, USA.

Mark McCurdy (M)

Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas, USA.

Emily H Warren (EH)

Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas, USA.

Jocelyn Gomez (J)

Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas, USA.

M Douglas Ris (MD)

Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas, USA.

Arnold C Paulino (AC)

Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Murali Chintagumpala (M)

Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH